Cite
APA Citation
Terauchi, Y., Fujiwara, H., Kurihara, Y., Suganami, H., Tamura, M., Senda, M., Gunji, R., & Kaku, K. (2019). long‐term safety and efficacy of the sodium–glucose cotransporter 2 inhibitor, tofogliflozin, added on glucagon‐like peptide‐1 receptor agonist in Japanese patients with type 2 diabetes mellitus: A 52‐week open‐label, multicenter, post‐marketing clinical study. Journal of diabetes investigation, 10(6), 1518–1526. http://access.bl.uk/ark:/81055/vdc_100094640631.0x00000e